These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31260789)

  • 21. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker.
    Beckman RA; Antonijevic Z; Kalamegham R; Chen C
    Clin Pharmacol Ther; 2016 Dec; 100(6):617-625. PubMed ID: 27509351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Umbrella and basket trials in oncology: ethical challenges.
    Strzebonska K; Waligora M
    BMC Med Ethics; 2019 Aug; 20(1):58. PubMed ID: 31443704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An efficient basket trial design.
    Cunanan KM; Iasonos A; Shen R; Begg CB; Gönen M
    Stat Med; 2017 May; 36(10):1568-1579. PubMed ID: 28098411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graphical search for two-stage designs for phase II clinical trials.
    Jung SH; Carey M; Kim KM
    Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication.
    He L; Ren Y; Chen H; Guinn D; Parashar D; Chen C; Yuan SS; Korostyshevskiy V; Beckman RA
    Stat Methods Med Res; 2022 Jul; 31(7):1207-1223. PubMed ID: 35404188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal three-stage designs for phase II cancer clinical trials.
    Chen TT
    Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trials.
    Zhang P; Li XN
    J Biopharm Stat; 2024 Mar; 34(2):251-259. PubMed ID: 38252040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.
    Meyer EL; Mesenbrink P; Dunger-Baldauf C; Fülle HJ; Glimm E; Li Y; Posch M; König F
    Clin Ther; 2020 Jul; 42(7):1330-1360. PubMed ID: 32622783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of precision oncology basket and umbrella trials for clinicians.
    Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
    CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.
    Yu Z; Wu L; Bunn V; Li Q; Lin J
    Ther Innov Regul Sci; 2023 Jul; 57(4):823-838. PubMed ID: 36871111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended two-stage adaptive designs with three target responses for phase II clinical trials.
    Kim S; Wong WK
    Stat Methods Med Res; 2018 Dec; 27(12):3628-3642. PubMed ID: 28535716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal flexible designs in phase II clinical trials.
    Chen TT; Ng TH
    Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal designs for phase II clinical trials with heterogeneous patient populations.
    Liu L; Cao S; Jung SH
    J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-stage optimal designs with survival endpoint when the follow-up time is restricted.
    Shan G; Zhang H
    BMC Med Res Methodol; 2019 Apr; 19(1):74. PubMed ID: 30943896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.